hotspot -WSS

hotspot

author：leisure time 2025-09-29 23:12:34 - browse：4

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： STAT Virtual Event: Putting AI to the Test

WSS

Chan Zuckerberg Biohub Chicago to focus on inflammation

Sana to lay off nearly a third of staff, de

What to expect at HLTH 2023, the health care industry conference

Was Amgen transparent enough on FDA's concern on cancer drug?

Ukraine and a new approach to mental health in war

Senators: Long

knowledge

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Wikipedia

Moonlake's readout produced a cash windfall. Risks remain

Why Charlie Gard's case is so disturbing to Americans

Jerome Adams on the need for new antivirals for Covid

Second xenotransplant done with gene

Virginia high school admissions case could be legal follow

Phenylephrine and the overlooked value of the placebo effect

What does generative AI mean for health care? We asked experts

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Moonlake's readout produced a cash windfall. Risks remain

Biotech stock slump in 2023: awaiting the turnaround

leisure time

Why age limits for politicians are a terrible idea

Biotech lab space demand falls sharply

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Physician executives need more than on

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Colorectal cancer study finds potential in overlooked immune cell

entertainment

focus

Wikipedia

leisure time